title: Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy?
abstract: OBJECTIVE
  Underpinned by increased confidence in cure of metastatic seminoma by chemotherapy during the past 12 years, three management strategies for Stage I seminoma have been evaluated by six collaborating centers within the Anglian Germ Cell Tumor Group. This paper evaluates the efficacy of surveillance, prophylactic radiotherapy and adjuvant chemotherapy, and discusses these differing management approaches.
  
  
  METHODS
  Patients were recruited into the study between 1982 and 1992. There was no randomization between treatment groups. Seventy-nine patients received prophylactic radiotherapy (median follow-up = 51 months), 67 patients had surveillance alone (median follow-up = 61 months) and 78 patients were treated with adjuvant single agent platinum (median follow-up = 44 months). Fifty-three of these patients received two courses of platinum (median follow-up = 51 months) and 25 patients received one course (median follow-up = 29 months, range 22-72 months).
  
  
  RESULTS
  There were 18 (27%) recurrences on surveillance, five (6%) after radiotherapy, one (1%) after two courses of adjuvant single agent platinum and none after one course of carboplatin. There was one death from testis cancer after radiotherapy and none after adjuvant chemotherapy treatments. Two patients died with drug resistant disease after relapse on surveillance. There was one death from a myocardial infarction after prophylactic radiotherapy and one death from suicide in the surveillance group. A retrospective quality of life questionnaire reviewing the incidence of early and late toxicity revealed no major differences though they suggest that those treated with one course adjuvant carboplatin had somewhat less sickness and an earlier return to work.
  
  
  CONCLUSIONS
  Single agent carboplatin appears well tolerated and is an effective adjuvant treatment for Stage I seminoma. A multicenter randomized trial of the different treatment modalities is required to further evaluate its use.
authors.affiliation: Dept. of Medical Oncology, Royal London Hospital, England.
authors.forename: R T
authors.initials: RT
authors.lastname: Oliver
authors.forename: P M
authors.initials: PM
authors.lastname: Edmonds
authors.forename: J Y
authors.initials: JY
authors.lastname: Ong
authors.forename: M J
authors.initials: MJ
authors.lastname: Ostrowski
authors.forename: A W
authors.initials: AW
authors.lastname: Jackson
authors.forename: H
authors.initials: H
authors.lastname: Baille-Johnson
authors.forename: M V
authors.initials: MV
authors.lastname: Williams
authors.forename: C R
authors.initials: CR
authors.lastname: Wiltshire
authors.forename: T
authors.initials: T
authors.lastname: Mott
authors.forename: W R
authors.initials: WR
authors.lastname: Pratt
mesh_terms: D000328:Adult; D016190:Carboplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D009919:Orchiectomy; D010865:Pilot Projects; D011788:Quality of Life; D018239:Seminoma / Q000628:therapy*; D013736:Testicular Neoplasms / Q000628:therapy*
chemical_list: D016190:Carboplatin